PubMed İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/11727/4810
Browse
4 results
Search Results
Item Septate Uterus. Resect or not? That is Not the Only Question(2022) Cok, Tayfun; 0000-0003-1244-7419; 36037812Item Evaluating the Impacts of Some Etiologically Relevant Factors on Excessive Gingival Display(2021) Cetin, Mehtap Bilgin; Sezgin, Yasemin; Akinci, Seray; Bakirarar, Batuhan; 33819318The literature offers limited and even conflicting information on the etiology of gummy smile. Therefore, this study aimed to evaluate smile line, hypermobile upper lip (HUL), altered passive eruption (APE), and short upper lip (SUL) distribution in a group of patients seeking dental treatment and to examine their effects on gummy smile. A total of 501 individuals (265 men, 236 women) were included in the study. The patients were grouped by gingival display, and presence of HUL, APE, and SUL were evaluated. Multivariate Logistic Regression analyses were performed to investigate the impact of possible risk factors on gummy smile. Of the individuals, 173 (34.5%) had a low smile line, 127 (25.3%) had an average smile line, 146 (29.1%) had a high smile line, and 55 (10.9%) were gummy smile patients. Individuals with gummy smile were younger than the individuals with low smile line (P < .001). As for the possible risk factors for gummy smile, age (odds ratio [OR]: 0.936; 95% CI: 0.901 to 0.972; P = .001), HUL (OR: 18.85; 95% CI: 7.82 to 45.44; P < .001), and APE (OR: 8.819; 95% CI: 3.894 to 19.973; P < .001) were found to be significant together. Gender and SUL/upper lip length were not found to have any impact on gummy smile. HUL is the primary factor that increases the probability of having gummy smile, followed by APE as the secondary factor. It seems reasonable to focus on correction of the HUL for treatment in most gummy smile patients.Item Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide(2020) Topkan, Erkan; Besen, Ali Ayberk; Ozdemir, Yurday; Kucuk, Ahmet; Mertsoylu, Huseyin; Pehlivan, Berrin; Selek, Ugur; 0000-0002-1932-9784; 0000-0002-2218-2074; 0000-0001-8120-7123; 0000-0002-7862-0192; 32565725; M-9530-2014; AAG-5629-2021; AAG-2213-2021; AAD-6910-2021Objectives. To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide. Methods. The retrospective data of GBM patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide were analyzed. For each patient, SII was calculated using the platelet, neutrophil, and lymphocyte measures obtained on the first day of treatment: SII=plateletsxneutrophils/lymphocytes. The receiver operating characteristic (ROC) curve analysis was utilized for the evaluation of optimal cut-off values for SII those linked with the outcomes. Primary and secondary endpoints constituted the overall (OS) and progression-free survival (PFS) per conveyance SII group. Results. A total of 167 patients were included. The ROC curve analysis identified the optimum SII cut-off at a rounded 565 value that significantly interacted with the PFS and OS and stratified patients into two groups: low-SII (SII<565; n=71) and high-SII (SII >= 565; n=96), respectively. Comparative survival analyses exhibited that the high-SII cohort had significantly shorter median PFS (6.0 versus 16.6 months; P<0.001) and OS (11.1 versus 22.9 months; P<0.001) than the low-SII cohort. The relationship between the high-SII and poorer PFS (P<0.001) and OS (P<0.001) further retained its independent significance in multivariate analysis, as well. Conclusions. The outcomes displayed here qualified the pretreatment SII as a novel independent prognostic index for predicting survival outcomes of newly diagnosed GBM patients undergoing postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide.Item Papillary renal cell carcinoma within a renal oncocytoma: Case report of very rare coexistence(2014) Ozer, Cevahir; Goren, Mehmet Resit; Egilmez, Tulga; Bal, Nebil; 25553171Renal oncocytomas accounts for 3% to 9% of primary renal neoplasms. The coexistence of renal cell carcinoma (RCC) within the oncocytoma is extremely rare. We report the case of an asyptomatic 74-year-old man with papillary RCC within oncocytoma managed with left radical nephrectomy.